drugset / Trial / NCT07018947

Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC

NCT07018947

Phase 2 Recruiting 90 enrolled Fundacion Clinic per a la Recerca Biomédica
RandomizedParallel-groupOpen-labelTreatment

Summary

Study to evaluate the efficacy and safety of the combination of Atezolizumab and Bevacizumab as neoadjuvant plus adjuvant treatment in Hepatocellular Carcinoma.

Timeline

Start
2026-06-02
Primary completion
2031-06
Completion
2031-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Atezolizumab Monoclonal antibody
Subject Bevacizumab Monoclonal antibody